PIK3CA and endometrioid tumor: Further studies, including more patients with charge-plus changing PIK3CA substitutions, in particular those with non-endometrioid tumors, and a better understanding of the molecular mechanism of p110α (and interaction partners) is required to confirm and extend our observations.